Literature DB >> 35130450

Borrelia burgdorferi Is a Poor Inducer of Gamma Interferon: Amplification Induced by Interleukin-12.

Frederik R van de Schoor1, Hedwig D Vrijmoeth1, Michelle A E Brouwer1, Hadewych J M Ter Hofstede1, Heidi L M Lemmers1, Helga Dijkstra1, Collins K Boahen1, Marije Oosting1, Bart-Jan Kullberg1, Joppe W Hovius2, Cees C van den Wijngaard3, Frank L van de Veerdonk1, Mihai G Netea1,4, Leo A B Joosten1.   

Abstract

Laboratory diagnosis of Lyme borreliosis (LB) is mainly based on serology, which has limitations, particularly in the early stages of the disease. In recent years there have been conflicting reports concerning a new diagnostic tool using the cytokine interferon-gamma (IFN-γ). Previous studies have generally found low concentrations of IFN-γ in early LB infection. The goal of this study is to investigate IFN-γ regulation during early LB and provide insights into the host response to B. burgdorferi. We performed in vitro experiments with whole blood assays and peripheral blood mononuclear cells (PBMCs) of LB patients and healthy volunteers exposed to B. burgdorferi and evaluated the IFN-γ response using ELISA and related interindividual variation in IFN-γ production to the presence of single nucleotide polymorphisms. IFN-γ production of B. burgdorferi-exposed PBMCs and whole blood was amplified by the addition of interleukin-12 (IL-12) to the stimulation system. This effect was observed after 24 h of B. burgdorferi stimulation in both healthy individuals and LB patients. The effect was highly variable between individuals, but was significantly higher in LB patients 6 weeks since the start of antibiotic treatment compared to healthy individuals. IL-12 p40 and IL-18 mRNA were upregulated upon exposure to B. burgdorferi, whereas IL-12 p35 and IFN-γ mRNA expression remained relatively unchanged. SNP Rs280520 in the downstream IL-12 pathway, Tyrosine Kinase 2, was associated with increased IFN-γ production. This study shows that IL-12 evokes an IFN-γ response in B. burgdorferi exposed cells, and that LB patients and healthy controls respond differently to this stimulation.

Entities:  

Keywords:  Borrelia; Lyme disease; antibody responses; borreliosis; erythema migrans; interferon-gamma

Mesh:

Substances:

Year:  2022        PMID: 35130450      PMCID: PMC8929378          DOI: 10.1128/iai.00558-21

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  99 in total

1.  B. burgdorferi sensu lato-induced inhibition of antigen presentation is mediated by RIP1 signaling resulting in impaired functional T cell responses towards Candida albicans.

Authors:  Michelle A E Brouwer; William Jones-Warner; Shafaque Rahman; Mariska Kerstholt; Anaísa V Ferreira; Marije Oosting; Guido J Hooiveld; Mihai G Netea; Leo A B Joosten
Journal:  Ticks Tick Borne Dis       Date:  2020-11-23       Impact factor: 3.744

Review 2.  IL-12p40: an inherently agonistic cytokine.

Authors:  Andrea M Cooper; Shabaana A Khader
Journal:  Trends Immunol       Date:  2006-11-28       Impact factor: 16.687

3.  Functional and Genomic Architecture of Borrelia burgdorferi-Induced Cytokine Responses in Humans.

Authors:  Marije Oosting; Mariska Kerstholt; Rob Ter Horst; Yang Li; Patrick Deelen; Sanne Smeekens; Martin Jaeger; Ekta Lachmandas; Hedwig Vrijmoeth; Mihaela Lupse; Mirela Flonta; Robert A Cramer; Bart Jan Kullberg; Vinod Kumar; Ramnik Xavier; Cisca Wijmenga; Mihai G Netea; Leo A B Joosten
Journal:  Cell Host Microbe       Date:  2016-11-03       Impact factor: 21.023

4.  Decreased interleukin-4 and increased gamma interferon production by peripheral blood mononuclear cells of patients with Lyme borreliosis.

Authors:  J Oksi; J Savolainen; J Pène; J Bòusquet; P Laippala; M K Viljanen
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

5.  In vivo production and function of IL-12 p40 homodimers.

Authors:  F P Heinzel; A M Hujer; F N Ahmed; R M Rerko
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

Review 6.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

7.  Recognition of Borrelia burgdorferi, the Lyme disease spirochete, by TLR7 and TLR9 induces a type I IFN response by human immune cells.

Authors:  Mary M Petzke; Andrew Brooks; Michelle A Krupna; Dana Mordue; Ira Schwartz
Journal:  J Immunol       Date:  2009-09-30       Impact factor: 5.422

8.  The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes.

Authors:  Chris Wallace; Deborah J Smyth; Meeta Maisuria-Armer; Neil M Walker; John A Todd; David G Clayton
Journal:  Nat Genet       Date:  2009-12-06       Impact factor: 38.330

9.  Multiple sclerosis susceptibility alleles in African Americans.

Authors:  B A Johnson; J Wang; E M Taylor; S J Caillier; J Herbert; O A Khan; A H Cross; P L De Jager; P-A F Gourraud; B C A Cree; S L Hauser; J R Oksenberg
Journal:  Genes Immun       Date:  2009-10-29       Impact factor: 2.676

10.  Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome.

Authors:  Alexandra Y Kreins; Michael J Ciancanelli; Satoshi Okada; Xiao-Fei Kong; Noé Ramírez-Alejo; Sara Sebnem Kilic; Jamila El Baghdadi; Shigeaki Nonoyama; Seyed Alireza Mahdaviani; Fatima Ailal; Aziz Bousfiha; Davood Mansouri; Elma Nievas; Cindy S Ma; Geetha Rao; Andrea Bernasconi; Hye Sun Kuehn; Julie Niemela; Jennifer Stoddard; Paul Deveau; Aurelie Cobat; Safa El Azbaoui; Ayoub Sabri; Che Kang Lim; Mikael Sundin; Danielle T Avery; Rabih Halwani; Audrey V Grant; Bertrand Boisson; Dusan Bogunovic; Yuval Itan; Marcela Moncada-Velez; Ruben Martinez-Barricarte; Melanie Migaud; Caroline Deswarte; Laia Alsina; Daniel Kotlarz; Christoph Klein; Ingrid Muller-Fleckenstein; Bernhard Fleckenstein; Valerie Cormier-Daire; Stefan Rose-John; Capucine Picard; Lennart Hammarstrom; Anne Puel; Saleh Al-Muhsen; Laurent Abel; Damien Chaussabel; Sergio D Rosenzweig; Yoshiyuki Minegishi; Stuart G Tangye; Jacinta Bustamante; Jean-Laurent Casanova; Stéphanie Boisson-Dupuis
Journal:  J Exp Med       Date:  2015-08-24       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.